Leerink Partners Maintains Outperform on CVS Health, Lowers Price Target to $112
Leerink Partners analyst Michael Cherny maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $119 to $112.
Share
Why It Matters
An expert thinks CVS is still a good company but worth a bit less money now. When experts lower their price guesses, watch to see if the company's business is actually changing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.